Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cenestin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Cenestin 0.3 mg Tablets | DRUG | 1 tablet daily |
| Placebo | OTHER | 1 tablet daily |
Inclusion Criteria: * Naturally or surgically postmenopausal * At least 12 months since last menses or 6 weeks past surgery * Minimum of 7 daily or 50 weekly moderate to severe hot flashes Exclusion Criteria: * Any contraindication to natural or synthetic estrogens
Cenestin is used to treat hot flashes. It is a small molecule therapy in the endocrine therapeutic area, developed by Teva Pharmaceutical Industries Limited. The drug has been studied in a Phase 3 clinical trial for the treatment of hot flashes in women.
Cenestin is made by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva is the developer responsible for the clinical program evaluating Cenestin for hot flashes.
Cenestin is in Phase 3 clinical development for hot flashes. The program includes one completed Phase 3 trial. As an investigational therapy, Cenestin has not been established as approved for this use based on the available development information.
Cenestin has been evaluated in one clinical trial: NCT00272935, titled A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 0.3 mg for the Treatment of Hot Flashes. This Phase 3 trial was completed, enrolled 400 participants, and was conducted in the United States.
The Phase 3 trial NCT00272935 was a randomized, double-blind, placebo-controlled study of Cenestin 0.3 mg for hot flashes. It enrolled 400 female participants aged 30 years and older in the United States and has been completed.